Extended Data Fig. 2: Receptor occupancy without target depletion following anti-TIGIT antibody therapy.
a. Representative data showing TIGIT staining in peripheral blood CD8 T cell subsets either before (TIGIT PreRx) or after (TIGIT Post C1) therapy with anti-TIGIT antibody. Naïve (CCR7 + RO-), central memory (CM; CCR7 + RO + ), effector memory (EM; CCR7-RO + ) and terminal effectors (Term EFF; CCR7-RO-) CD8 T cells. b. Proportions of naïve, CM, EM and Term EFF CD8 T cells in blood and bone marrow biospecimens obtained from patients pre (TIGIT PreRx) and post cycle 1 (TIGIT Post C1) following therapy with anti-TIGIT antibody. Data points represent biologically independent samples. Blood (TIGIT PreRx: n = 8, TIGIT Post C1: n = 17). Bone marrow (TIGIT PreRx: n = 3, TIGIT Post C1: n = 3). No differences were seen in proportions of circulating or bone marrow CD8 cell subsets before or after therapy with anti-TIGIT antibody (p=non-significant, 2 tailed Mann Whitney; naïve PreRx vs Post C1, CM PreRx vs Post C1, EM PreRx vs Post C1 and Term EFF PreRx vs Post C1). Box plots represent median with Q1-Q3 and error bars as min-max. c. Pre-treatment peripheral blood mononuclear cells from a patient on the TIGIT arm were thawed and cultured alone or with autologous plasma from cycle 1 day 15 (C1D15) for one hour. Staining for TIGIT expression on NK, CD8 and regulatory T cells (Treg) was assessed using mass cytometry.
